Exagen_Full_CMYK_Print.jpg
Exagen Inc. to Participate in December Investor Conferences
November 18, 2020 16:05 ET | Exagen Inc.
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Exagen_Full_CMYK_Print.jpg
Exagen Inc. Reports Third Quarter 2020 Results
November 10, 2020 16:05 ET | Exagen Inc.
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported...
Equillium_Square_Logo.png
Equillium to Present at Investor Conferences in November 2020
November 10, 2020 08:35 ET | Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Exagen_Full_CMYK_Print.jpg
Exagen Inc. To Participate in November Investor Conferences
November 09, 2020 08:25 ET | Exagen Inc.
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Equillium_Square_Logo.png
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
November 06, 2020 08:35 ET | Equillium
100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date Complete response observed in seven of eight responding patients EQUATE Phase 1b topline data...
Exagen_Full_CMYK_Print.jpg
Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection
November 02, 2020 08:25 ET | Exagen Inc.
SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Exagen_Full_CMYK_Print.jpg
New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors
October 12, 2020 16:05 ET | Exagen Inc.
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced...
Dr Benjamin photo
18th U.S. Surgeon General Joins Scipher Medicine
October 08, 2020 08:00 ET | Scipher Medicine Corporation
WALTHAM, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with most effective therapy, has appointed former United States Surgeon General...
Equillium_Square_Logo.png
Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020
September 17, 2020 16:07 ET | Equillium
LA JOLLA, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium Announces Proposed Public Offering of Common Stock
August 13, 2020 16:02 ET | Equillium
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...